| Literature DB >> 35736464 |
Jakub Idkowiak1,2, Grażyna Kubiak-Tomaszewska3, Paulina Gątarek4, Łukasz Marczak5, Joanna Kałużna-Czaplińska4, Wiesław Tarnowski6, Mariusz Uryszek6, Barbara Bobrowska-Korczak1.
Abstract
Lesniowski-Crohn's disease (CD) is a type of chronic inflammatory bowel disease (IBD) of uncertain etiology. Initially, pharmacological management is undertaken; however, surgical intervention is necessary to improve life quality and relieve symptoms in most cases. Here changes are reported in blood metabolome that occurred three days after the ileo-colic region resection in the case of seven patients. Alterations are observed in levels of metabolites associated with multiple mitochondrial pathways, based on the Metabolite Set Enrichment Analysis, reflecting a high energy demand in the post-operative period. As most of these metabolites are also essential nutrients supplied from foods, we believe that our results might contribute to the discussion on perioperative nutrition's role in enhanced recovery.Entities:
Keywords: Gas Chromatography-Mass Spectrometry (GC-MS); Lesniowski-Crohn’s disease; blood plasma metabolome; metabolomics
Year: 2022 PMID: 35736464 PMCID: PMC9228040 DOI: 10.3390/metabo12060529
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Summary of patients’ clinical data.
| Patient ID | Protein [g/dL] | Electrolytes | Glucose [mg/dL] | CRP [mg/L] | Creatinine [mg/dL] | AST [U/L] | ALT [U/L] | Urea [mg/dL] | Coagulation System [s] | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Albumins | Na [mM] | K [mM] | Ca [mg/dL] | Mg [mg/dL] | Pinorg. [mg/dL] | PT | INR | APTT | |||||||||||||||||||||||
| B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | |
| 1 | 5.0 | 5.1 | 2.9 | 2.3 | 143 | 139 | 4.5 | 4.4 | 8.5 | 8.2 | 2.3 | 2.6 | 3.5 | 3.8 | 97 | 71 | 52 | 95 | 0.80 | 0.82 | 18 | 20 | 13 | 26 | 46 | 42 | 11.9 | 12.2 | 0.99 | 1.01 | 30 | 32 |
| 2 | 6.2 | 5.4 | 3.1 | 3.1 | 138 | 137 | 4.4 | 4.5 | 7.6 | 8.3 | 1.7 | 2.1 | 1.8 | 3.5 | 75 | 84 | 193 | 225 | 0.58 | 0.65 | no data | no data | no data | no data | 8 | 16 | 13.7 | 15.8 | 1.14 | 1.31 | 33 | 40 |
| 3 | 6.7 | 6.4 | 3.0 | 2.7 | 140 | 144 | 4.0 | 3.7 | 8.2 | 7.6 | 1.6 | 2.1 | 3.3 | 3.7 | 106 | 83 | 85 | 132 | 0.88 | 0.78 | 15 | 17 | 23 | 42 | 18 | 41 | 13.3 | 15.8 | 1.17 | 1.41 | 40 | 40 |
| 4 | 5.7 | 4.9 | 2.8 | 2.2 | 140 | 139 | 4.0 | 2.7 | 7.8 | 7.9 | 1.8 | 1.9 | 3.2 | 2.9 | 113 | 107 | 2 | 126 | 0.73 | 0.63 | 16 | 22 | 34 | 29 | 15 | 24 | 11.2 | 10.7 | 0.93 | 0.99 | 30 | 33 |
| 5 | 5.9 | 5.7 | 2.8 | 2.8 | 140 | 142 | 3.3 | 5.0 | 8.1 | 8.8 | 2.0 | 2.8 | 3.1 | 3.0 | 101 | 82 | 76 | 29 | 0.85 | 0.97 | 44 | 52 | 39 | 66 | 20 | 19 | 12.3 | 11.8 | 1.10 | 1.04 | 32 | 28 |
| 6 | 6.8 | 7.0 | 4.2 | 3.8 | 140 | 138 | 4.1 | 4.3 | 8.8 | 8.9 | 1.7 | 1.8 | 2.4 | 3.3 | 60 | 99 | 2 | 84 | 1.15 | 0.93 | 21 | 33 | 15 | 36 | 25 | 26 | 11.3 | 11.2 | 0.99 | 0.94 | 29 | 31 |
| 7 | 6.2 | 6.2 | 2.8 | 3.0 | 139 | 141 | 4.8 | 4.6 | 8.1 | 8.4 | 2.0 | 1.6 | 2.9 | 2.7 | 76 | 91 | 181 | 100 | 0.65 | 0.69 | 16 | 11 | 23 | 35 | 14 | 26 | 11.5 | 11.9 | 1.02 | 1.06 | 33 | 33 |
B—before surgery; A—after surgery.
Statistical analysis of clinical characteristics of patients in the study.
| Clinical Parameter | Before | After | Laboratory Norms | Statistic | FDR Adjusted | Remarks | |
|---|---|---|---|---|---|---|---|
| Total protein [g/dL] | 6.1 ± 0.5 | 5.8 ± 0.8 | 6.0–8.3 | −1.56 | 0.177 | 0.40 | ns |
| Albumin [g/dL] | 3.1 ± 0.5 | 2.8 ± 0.5 | 3.4–5.4 | −2.04 | 0.09 | 0.40 | ns |
| Total cholesterol [mg/dL] | 121.3 ± 30.6 | 157.0 ± 19.1 | <200 | - | - | - | 1 |
| TG [mg/dL] | 76.0 ± 33.8 | 118.7 ± 18.6 | <150 | - | - | - | 1 |
| Na [mM] | 140.0 ± 1.5 | 140.0 ± 2.4 | 135–147 | 0.00 | 1.00 | 1.00 | ns |
| K [mM] | 4.2 ± 0.5 | 4.2 ± 0.8 | 3.0–5.5 | 0.04 | 0.97 | 1.00 | ns |
| Ca [mg/dL] | 8.1 ± 0.4 | 8.3 ± 0.5 | 8.6–10.3 | 0.84 | 0.43 | 0.58 | ns |
| Mg [mg/dL] | 1.9 ± 0.2 | 2.1 ± 0.4 | 1.8–2.4 | 1.80 | 0.12 | 0.40 | ns |
| Phosphorus (inorganic) [mg/dL] | 2.9 ± 0.6 | 3.3 ± 0.4 | 2.5–4.5 | 1.43 | 0.20 | 0.40 | ns |
| Glucose [mg/dL] | 89.7 ± 19.5 | 88.1 ± 12.0 | 72.0–99.0 | −0.17 | 0.87 | 0.99 | ns |
| CRP [mg/L] | 84.3 ± 77.2 | 113.0 ± 59.7 | <3.0 | 1.07 | 0.33 | 0.47 | ns |
| Creatinine [mg/dL] | 0.81 ± 0.19 | 0.78 ± 0.13 | 0.84–1.21 | −0.54 | 0.61 | 0.75 | ns |
| AST [U/L] | 21.7 ± 11.1 | 25.8 ± 14.7 | 8.0–48.0 | 1.74 | 0.14 | 0.40 | ns, 2 |
| ALT [U/L] | 24.5 ± 10.3 | 39.0 ± 14.4 | 7.0–55.0 | 3.22 | 0.02 | 0.37 | p, ns, 2 |
| Urea [mg/dL] | 20.9 ± 12.3 | 27.7 ± 10.1 | 7.0–20.0 | 1.97 | 0.10 | 0.40 | ns |
| PT [s] | 12.2 ± 1.0 | 12.7 ± 2.1 | 11.0–13.5 | 1.22 | 0.27 | 0.47 | ns |
| INR [s] | 1.0 ± 0.1 | 1.1 ± 0.2 | 0.8–1.1 | 1.44 | 0.20 | 0.40 | ns |
| APTT [s] | 32.4 ± 3.5 | 33.8 ± 4.6 | 30.0–40.0 | 1.10 | 0.31 | 0.47 | ns |
ns—not significant after FDR correction (FDR corrected p-value < 0.05); 1 Total cholesterol and TG were measured for 3 patients only; 2 AST and ALT were measured for 6 patients; p—raw p-value significant (p-value < 0.05).
Statistical analysis of clinical characteristics of patients in the study.
| Metabolite | Class of | RT | Mean [a.u.] | C.V. | Mean [a.u.] | C.V. | After/Before | FDR | |
|---|---|---|---|---|---|---|---|---|---|
| Glycerol-3-phosphate | Phosphoric acid deriv. | 13.12 | 0.144 | 0.518 | 0.622 | 0.657 | 4.33 | 0.00125 | 0.029 |
| α-Tocopherol | Lipids | 23.26 | 0.291 | 0.886 | 0.991 | 0.599 | 3.40 | 0.00845 | 0.140 |
| 1-Monopalmitoylglycerol | Lipids | 19.17 | 1.385 | 1.209 | 3.858 | 0.833 | 2.79 | 0.00010 | 0.004 |
| 2-Monopalmitoylglycerol | Lipids | 18.9 | 0.102 | 0.786 | 0.279 | 0.703 | 2.74 | 0.00006 | 0.004 |
| 1-Monostearoylglycerol | Lipids | 20.34 | 0.864 | 0.751 | 2.272 | 1.045 | 2.63 | 0.00008 | 0.004 |
| Succinic acid | Carboxylic acids | 8.46 | 1.482 | 0.841 | 3.705 | 1.055 | 2.50 | 0.04682 | 0.362 |
| 2-Monostearoylglycerol | Lipids | 20.1 | 0.075 | 0.534 | 0.176 | 0.814 | 2.35 | 0.00012 | 0.004 |
| L-Cysteine | Amino acids | 11.1 | 1.938 | 0.929 | 4.214 | 0.444 | 2.17 | 0.03241 | 0.342 |
| L-Methionine | Amino acids | 10.74 | 1.645 | 0.848 | 3.364 | 0.462 | 2.05 | 0.04194 | 0.362 |
| L-Lysine | Amino acids | 14.36 | 2.989 | 0.930 | 5.814 | 0.257 | 1.95 | 0.02451 | 0.315 |
| Benzoic acid ** | Carboxylic acids | 7.81 | 0.922 | 0.560 | 1.449 | 0.361 | 1.57 | 0.00511 | 0.099 |
| 3,4-Dihydroxybutanoic acid | Carboxylic acids | 9.8 | 0.452 | 0.728 | 0.151 | 0.637 | 0.33 | 0.02717 | 0.315 |
| Galactopyranose | Sugars | 14.32 | 7.096 | 1.336 | 0.661 | 1.462 | 0.09 | 0.01396 | 0.202 |
| Ribonic acid * | Sugar deriv. | 13.35 | 7/7 | 2/7 | NA |
* Metabolite was not determined in the blood plasma of 5 patients after the surgery. ** Identification uncertain. NA—not applied.
Figure 1Box plots illustrating changes in levels of selected metabolites before and after the surgery.
Figure 2(A) Volcano plot shows metabolites with the raw p-value < 0.05 and simultaneously log2 (fold change) above 0.5; (B) Circular dendrogram and heatmap created using the set of biologically relevant metabolites. Further, 0–1 scaling was applied to normalize the abundance of individual metabolites in patients’ plasma prior- and post-surgery.
Figure 3Results of the Metabolite Set Enrichment Analysis with Fold Enrichment higher than 4.
General patients characteristics.
| Patient ID | Gender | Age | Disease State |
|---|---|---|---|
| 1 | M | 42 | active |
| 2 | F | 29 | active |
| 3 | M | 43 | active |
| 4 | F | 52 | active |
| 5 | F | 60 | active |
| 6 | M | 24 | active |
| 7 | F | 26 | active |